Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biogen Inc. (BIIB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a Nasdaq-listed biotechnology company, Biogen uses these filings to report financial results, material events and governance matters that are important for investors evaluating its activities in neurology, rare diseases and immunology.
Recent Form 8-K filings show how Biogen communicates results of operations and financial condition, including quarterly earnings press releases and preliminary estimates of acquired in-process research and development, upfront and milestone expenses. The company explains that these expenses arise from collaboration and license agreements and are presented as a separate line item in its condensed consolidated statements of income. Other 8-K filings cover shareholder votes at the annual meeting, such as the election of directors and ratification of the independent registered public accounting firm.
Through this page, users can review Biogen’s SEC-reported information alongside Stock Titan’s AI-powered tools, which can help summarize lengthy filings and highlight key items such as collaboration-related charges, capital allocation decisions and governance outcomes. Investors interested in Biogen’s partnerships, pipeline investments and financial reporting practices can use these filings to understand how the company accounts for its research collaborations, including those involving antisense oligonucleotides, monoclonal antibodies and emerging modalities.
In addition to 8-Ks, this page can link to other Biogen filings available on EDGAR, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company provides more detailed discussion of its business, risk factors and financial statements. Together, these documents form the regulatory record that underpins fundamental analysis of BIIB.
SEC Form 4 filed on 06/18/2025 reveals that Biogen Inc. (BIIB) director Susan K. Langer acquired 2,370 shares of common stock on 06/17/2025. The transaction is coded “A,” indicating an acquisition, and carries a stated price of $0 per share, characteristic of a director equity grant rather than an open-market purchase. Following the award, Langer’s direct beneficial ownership rises to roughly 5,129 shares. No derivative security activity or additional transactions were reported. The filing was signed by attorney-in-fact Wendell Taylor on behalf of the director. No other material changes or footnotes accompany the filing.
Biogen Inc. (BIIB) Director Caroline Dorsa reported acquiring 3,160 shares of Common Stock on June 17, 2025. The shares were awarded at a price of $0, suggesting this was a stock grant as part of director compensation.
Following this transaction, Dorsa now beneficially owns a total of 31,002 shares directly. The filing indicates this was a straightforward acquisition with no derivative securities involved in the transaction.
The Form 4 was signed by Wendell Taylor as attorney-in-fact for Caroline Dorsa on June 18, 2025, within the required reporting timeline. This transaction appears to be part of regular director compensation practices rather than open market trading activity.